HALF-LIFE: 18-24 hours
PROTEIN BOUND: N/A
METABOLISM: None, excreted unchanged in kidneys
INITIAL DOSE: 300mg-600mg PO per day (divided doses)
TARGET DOSING RANGE: 600mg-1,200mg per day (Target level 0.8-1.0 mEq/L)
BEST TIME TO DOSE: Any
TYPICAL DOSING: Initial 300mg-600mg at bedtime or divided in two doses. Gradually increase dose to target serum level of 0.6-1.0 mEq/L. Max dose is generally 2,400mg/day. An increase or decrease of 300mg/day changes serum Li levels approximately 0.25 mEq/L (rough estimate)
PREGNANCY: Avoid if possible (but not an absolute contraindication) – Risk of Epstein Anomaly (downward displacement of tricuspid valve into a malfunctioning right ventricle)
BREASTFEEDING: Avoid if possible (but not an absolute contraindication)
1) Acute mania
2) Bipolar Disorder Maintenance in children and adults
Nausea, diarrhea, upset stomach, frequent urination (nephrogenic diabetes insipidus), increased thirst, tremors, headache, fatigue, lethargy, emotional blunting/flatness, worsening of acne, worsening of psoriasis, increased white blood cell count. Mild side effects are common when starting lithium (especially nausea, upset stomach, daytime fatigue) but typically go away after about 5 days of consistently taking the medication as prescribed.
- Lithium + Haloperidol may increase the risk of NMS and delirium
- Lithium may cause abnormal involuntary movements
- Lithium may increase the risk of serotonin syndrome if administered with serotonergic agents
The following medications/drugs commonly INCREASE lithium levels:
- NSAIDs (e.g., naproxen, Ibuprofen)
- Low sodium levels (hyponatremia)
- ACE Inhibitors (e.g., Lisinopril)
- Diuretics (e.g., thiazide and loop diuretics)
The following medications/substances commonly DECREASE lithium levels:
- High sodium levels/high salt diet (e.g., hypernatremia)
Mechanism(s) of Action
Lithium’s interactions with the brain are complex and include:
- Desensitizing presynaptic 5HT-1A auto receptors in the raphe nuclei and thereby increasing serotonin release
- Decoupling G-protein linked production of second messengers
- Directly increasing transcription of fast response genes (e.g. KREB, PHOS, and JUN)
Proposed Mechanisms of Action of Lithium:
- Alters sodium transport in myocytes/neurons
- Alters metabolism of catecholamines (DA, NE, Epinephrine)
- Alters intracellular signaling via second messengers (IP3 and PKC pathways)
- Lithium is a cation metal first used in the 19th century to treat gout and discovered by John Cade in 1949 to exert anti-manic effects
- Benign leukocytosis (elevated white blood cell count) is due to demarginalization of white blood cells (WBCs)
- Optimal plasma concentrations for treatment of bipolar mood disorder are 0.8 to 1.2 meq/L, however, toxic signs and symptoms may begin at concentrations as low as 1.5 meq/L and serious toxicity with risk of permanent neurological injury may occur at concentrations as low as 2.0 meq/L.
- Lithium is easily dialyzed and can be administered to patients on hemodialysis (Give dose after dialysis treatment)
- Effective for chronic suicidal thoughts in bipolar and unipolar depression
- Effective for aggressive and violent behaviors
- Propranolol is an effective treatment for tremors associated with lithium
- Bradycardia, cardiac arrhythmia, sinus node dysfunction may be seen with lithium therapy
|Dehydration||Vomiting||Monitor lithium levels every 2-4 hours|
|Hyponatremia (low sodium)||Diarrhea||Intravenous (IV) Fluids|
|Low GFR (Glomerular Filtration Rate)||Ataxia||Hemodialysis recommended if Lithium level >2.5 mEq/L with signs of neurotoxicity|
|Renal Impairment/Failure/Disease||Confusion||Hemodialysis recommended if no improvement with IV fluids|
|Drug Interactions||Tremor||Hemodialysis recommended if Lithium level >4.0 mEq/L|
|Diuretics (except loop diuretics)||Slurred Speech|
|NSAIDs (except aspirin)||Seizures|
|ACE Inhibitors||Abnormal Movements|
Lithium Level Monitoring
|Lithium Monitoring||Target Lithium Level||Recommended Labs|
|Acute Mania||0.8-1.2mEq/L||Baseline: CBC, CMP, Cr, BUN, TSH, Weight, EKG (in pts>50yo or with cardiac disease)|
|Maintenance||0.6-1.0 mEq/L||After 1 week, 1 month, 6 months, and 12 months of starting lithium: Lithium Level, TSH, BUN/Cr, Electrolytes, monitor weight|
|Every 6-12 months: Lithium Level, TSH, BUN/Cr, Electrolytes, monitor weight|
|NOTE: Check Lithium levels after 4-5 half lives (blood should be collected prior to next dose); Also check lithium levels after dosage changes, addition of other drugs, or if suspecting toxicity|
- Cooper, J. R., Bloom, F. E., & Roth, R. H. (2003). The biochemical basis of neuropharmacology (8th ed.). New York, NY, US: Oxford University Press.
- Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Introduction to neuropsychopharmacology. Oxford: Oxford University Press.
- Puzantian, T., & Carlat, D. J. (2016). Medication fact book: for psychiatric practice. Newburyport, MA: Carlat Publishing, LLC.
- J. Ferrando, J. L. Levenson, & J. A. Owen (Eds.), Clinical manual of psychopharmacology in the medically ill(pp. 3-38). Arlington, VA, US: American Psychiatric Publishing, Inc.
- Schatzberg, A. F., & DeBattista, C. (2015). Manual of clinical psychopharmacology. Washington, DC: American Psychiatric Publishing.
- Schatzberg, A. F., & Nemeroff, C. B. (2017). The American Psychiatric Association Publishing textbook of psychopharmacology. Arlington, VA: American Psychiatric Association Publishing.
- Stahl, S. M. (2014). Stahl’s essential psychopharmacology: Prescriber’s guide (5th ed.). New York, NY, US: Cambridge University Press.
- Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY, US: Cambridge University Press.
- Whalen, K., Finkel, R., & Panavelil, T. A. (2015). Lippincotts illustrated reviews: pharmacology. Philadelphia, PA: Wolters Kluwer.